Trial Profile
First-in-human phase Ib trial investigating the tolerability of exenatide [ORMD 0901] when administered 60 min before a glucose load in healthy males
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2012
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2010 Results reported at the Scientific Sessions of the American Diabetes Association (ADA), according to an Oramed Pharmaceuticals media release.
- 14 Sep 2009 New trial record.